

ValÃ©rie Boige

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6136506/publications.pdf>

Version: 2024-02-01

29
papers

765
citations

687220

13
h-index

610775

24
g-index

30
all docs

30
docs citations

30
times ranked

1505
citing authors

#	ARTICLE	IF	CITATIONS
1	Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.. Journal of Clinical Oncology, 2022, 40, 3555-3555.	0.8	0
2	Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus. European Journal of Cancer, 2021, 142, 147-149.	1.3	2
3	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101590.	0.7	17
4	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patientsâ€™ data from 3 phase III studies. Cancer Treatment Reviews, 2021, 97, 102202.	3.4	14
5	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. Clinical Cancer Research, 2021, 27, 4768-4780.	3.2	25
6	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. European Journal of Cancer, 2020, 137, 117-126.	1.3	16
7	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. European Journal of Cancer, 2020, 135, 103-112.	1.3	11
8	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. British Journal of Cancer, 2020, 122, 957-962.	2.9	4
9	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). Clinical Colorectal Cancer, 2020, 19, 301-310.e1.	1.0	9
10	Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy â€” a randomized phase II study – SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol. BMC Cancer, 2020, 20, 74.	1.1	9
11	Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.. Journal of Clinical Oncology, 2020, 38, 4007-4007.	0.8	123
12	Role of precision medicine for patients with advanced biliary tract cancers.. Journal of Clinical Oncology, 2020, 38, 552-552.	0.8	0
13	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. EBioMedicine, 2019, 46, 94-104.	2.7	24
14	Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.. Journal of Clinical Oncology, 2019, 37, 3550-3550.	0.8	1
15	Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS3159-TPS3159.	0.8	0
16	PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy.. Journal of Clinical Oncology, 2019, 37, TPS3619-TPS3619.	0.8	0
17	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). Digestive and Liver Disease, 2018, 50, 305-307.	0.4	13
18	Reply to M. Mo et al. Journal of Clinical Oncology, 2018, 36, 2452-2453.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , 2018, 36, 674-681.	0.8	70
20	Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?. <i>European Journal of Cancer</i> , 2018, 100, 94-103.	1.3	20
21	Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 1304-1311.	0.7	9
22	First-line treatment in metastatic colorectal cancer: Important or crucial?. <i>European Journal of Cancer</i> , 2017, 84, 363-366.	1.3	4
23	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3640-3646.	0.7	25
24	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. <i>European Journal of Cancer</i> , 2017, 87, 122-130.	1.3	120
25	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2016, 48, 1498-1502.	0.4	8
26	Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 78-83.	1.0	0
27	Systemic treatment of advanced hepatocellular carcinoma: From disillusion to new horizons. <i>European Journal of Cancer</i> , 2015, 51, 327-339.	1.3	63
28	FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 vs FFCD 0802). <i>Digestive and Liver Disease</i> , 2015, 47, 271-272.	0.4	13
29	Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. <i>Journal of Hepatology</i> , 2012, 56, 609-617.	1.8	161